Wells Fargo analyst Jim Birchenough lowered the firm’s price target on uniQure to $14 from $24 and keeps an Equal Weight rating on the shares following the Huntington’s disease data update. The firm continues to see risk in the program and notes new question emerging from the data on HTT biomarker.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on QURE:
- uniQure price target lowered to $27 from $45 at Chardan
- uniQure selloff on AMT-130 update ‘appears overdone,’ says H.C. Wainwright
- uniQure Tanks on Interim Data in Huntington’s Disease
- uniQure announces update on Phase I/II trial of AMT-130
- uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease